{"schema_version":"secwatch.filing_event.v1","accession":"0001935979-25-000016","form_type":"8-K","ticker":"BHVN","cik":"0001935979","company_name":"Biohaven Ltd.","filed_at":"2025-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.601515+00:00","generated_at":"2026-05-25T21:21:31.808085+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"medium","headline":"Biohaven reports $489M cash; FDA accepts troriluzole NDA with Priority Review for SCA","bullets":["Cash & securities totaled $489M as of Dec 31, 2024; R&D expenses Q4 2024 were $167.5M (vs $134.8M Q4 2023).","FDA accepted troriluzole NDA for spinocerebellar ataxia with Priority Review; PDUFA date in 3Q 2025.","BHV-1300 (IgG degrader) achieved up to 84% reduction of total IgG in Phase 1; Phase 2 in Graves' disease expected mid-2025.","Next-gen TRAP degraders BHV-1400 (IgAN) and BHV-1600 (PPCM) advanced; Phase 1 completion expected 1H 2025.","Multiple pipeline milestones expected: BHV-7000 MDD topline 2H 2025, BHV-8000 Parkinson's study initiation 1H 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001935979-25-000016","json":"https://secwatch.observer/filing/0001935979-25-000016.json","markdown":"https://secwatch.observer/filing/0001935979-25-000016.md","text":"https://secwatch.observer/filing/0001935979-25-000016.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1935979/000193597925000016/0001935979-25-000016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1935979/000193597925000016/bhvn-20250303.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T21:21:31.808085+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}